Purification and initial characterization of Plasmodium falciparum K+ channels, PfKch1 and PfKch2 produced in Saccharomyces cerevisiae

Resistance towards known antimalarial drugs poses a significant problem, urging for novel drugs that target vital proteins in the malaria parasite Plasmodium falciparum. However, recombinant production of malaria proteins is notoriously difficult. To address this, we have investigated two putative K...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Microbial cell factories 2020-09, Vol.19 (1), p.1-16, Article 183
Hauptverfasser: Molbaek, Karen, Tejada, Maria, Ricke, Christina Hoeier, Scharff-Poulsen, Peter, Ellekvist, Peter, Helix-Nielsen, Claus, Kumar, Nirbhay, Klaerke, Dan A, Pedersen, Per Amstrup
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Resistance towards known antimalarial drugs poses a significant problem, urging for novel drugs that target vital proteins in the malaria parasite Plasmodium falciparum. However, recombinant production of malaria proteins is notoriously difficult. To address this, we have investigated two putative K.sup.+ channels, PfKch1 and PfKch2, identified in the P. falciparum genome. We show that PfKch1 and PfKch2 and a C-terminally truncated version of PfKch1 (PfKch1.sup.1-1094) could indeed be functionally expressed in vivo, since a K.sup.+-uptake deficient Saccharomyces cerevisiae strain was complemented by the P. falciparum cDNAs. PfKch1.sup.1-1094-GFP and GFP-PfKch2 fusion proteins were overexpressed in yeast, purified and reconstituted in lipid bilayers to determine their electrophysiological activity. Single channel conductance amounted to 16 [+ or -] 1 pS for PfKch1.sup.1-1094-GFP and 28 [+ or -] 2 pS for GFP-PfKch2. We predicted regulator of K.sup.+-conductance (RCK) domains in the C-terminals of both channels, and we accordingly measured channel activity in the presence of Ca.sup.2+.
ISSN:1475-2859
1475-2859
DOI:10.1186/s12934-020-01437-7